Semaglutide is a 31–amino-acid synthetic peptide analog of human GLP-1. The foundational molecule behind the modern GLP-1 therapeutic class, it is widely cited in published metabolic and endocrine research. Supplied as a lyophilized powder with 3rd-party HPLC verification and full Certificate of Analysis per lot.
Semaglutide is described in the literature as the foundational long-acting GLP-1 receptor agonist of the modern incretin class. Developed by Novo Nordisk (trade names Ozempic, Wegovy, and Rybelsus), it is the molecule that established the category now dominated by weekly GLP-1 therapies.
Structurally, semaglutide is a 31-residue modified analog of native GLP-1. It carries two key modifications relative to the parent hormone: an α-aminoisobutyric acid (Aib) substitution at position 2 that blocks DPP-4 proteolysis, and a γ-glutamic-acid/2×OEG/C18 fatty diacid conjugate at position 26 (K26) that drives high-affinity binding to serum albumin.
Published pharmacology studies describe semaglutide as a selective agonist at the GLP-1 receptor. The reported downstream effects include glucose-dependent insulin secretion, slowed gastric emptying, and central appetite modulation mediated through hypothalamic GLP-1R signaling. Unlike tirzepatide, semaglutide has no reported activity at the GIP receptor.
Supplied as a white to off-white lyophilized powder with a molecular weight of 4,113 Da. Reported solubility is in bacteriostatic water or sodium chloride 0.9%. The lipidated structure drives a reported terminal half-life of approximately seven days, which is what enables once-weekly pharmacokinetics in the clinical formulations.
Semaglutide's design established the template — Aib at position 2 plus a lipidation strategy at a C-terminal lysine — that later molecules including tirzepatide and retatrutide have iterated on.
The above summarizes published research literature and regulatory filings. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.
Every lot is tested by an independent 3rd-party analytical laboratory before release. The standard analytical panel includes reverse-phase HPLC (minimum 99.5% release spec, typically >99.9%), mass spectrometry for identity confirmation, Karl Fischer for water content, LAL assay for endotoxin (<0.25 EU/mL), bioburden, and sterility testing per USP <71>.
The resulting Certificate of Analysis PDF is attached to every order and is lookup-able by lot number after the fact.
Structurally, they're both synthetic peptide analogs designed as long-acting incretin agonists, but they target different receptor profiles. Semaglutide is a mono-agonist at the GLP-1 receptor only. Tirzepatide is a dual-agonist — it binds both GLP-1 and GIP.
Reported head-to-head comparative data is published in the SURPASS-2 trial (NEJM 2021), which documented differences in efficacy endpoints. From a chemistry standpoint, semaglutide uses a C18 lipidation at K26 with a different spacer structure, while tirzepatide uses a C20 lipidation at K20.
Shipped at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way without cold-chain logistics. Tracked via carrier; signature not required.
Upon receipt, store the unopened lyophilized vial refrigerated at 2–8°C and protected from light. Literature reports the lyophilized form is stable for up to 24 months under these conditions. If reconstituted per published solubility data, the solution is typically stable for approximately 28 days at 2–8°C. Do not freeze.
Semaglutide is a 31-amino-acid synthetic peptide analog of human GLP-1, with a molecular formula of C187H291N45O59 and a molecular weight of approximately 4,113 Da. It carries an Aib (α-aminoisobutyric acid) substitution at position 2 — blocking DPP-4 proteolysis — and a γGlu-2×OEG-C18 fatty diacid conjugate at position 26 (K26) that drives high-affinity serum albumin binding.
Supplied as a white to off-white lyophilized powder. The full primary structure and reference data are in the Compound Profile section above.
All compounds are synthesized by qualified partner laboratories operating under standard peptide synthesis practices. Synthesis records, raw material provenance, and release testing are documented in the lot file.
Each lot is independently verified by a 3rd-party analytical lab — not our in-house testing — before release. The COA PDF identifies the release lab, the method, and the analyst.
Domestic US shipping to all 50 states via USPS / UPS. Tracking provided at dispatch. International shipping is evaluated on a case-by-case basis due to jurisdictional import regulations.
All products offered on this site are intended for laboratory research purposes only. They are not for human consumption, oral ingestion, or any form of in-vivo use in humans or animals. These compounds are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease.
By placing an order you acknowledge that you are a qualified researcher over the age of 21 and that you assume all responsibility for handling, storage, and end use of the compounds in accordance with applicable law.
HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.
⚠ ALL PRODUCTS ARE INTENDED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION, ORAL INGESTION, OR ANY FORM OF IN-VIVO USE IN HUMANS OR ANIMALS. THESE COMPOUNDS ARE NOT MEDICINES OR DRUGS AND HAVE NOT BEEN APPROVED BY THE FDA. BY PLACING AN ORDER YOU ACKNOWLEDGE YOU ARE A QUALIFIED RESEARCHER OVER THE AGE OF 21.